US seed and pesticide giant Monsanto said Wednesday it had received a proposal from Bayer which was "unsolicited, non-binding," but nevertheless reviewed by the company for "due diligence, regulatory approvals and other conditions."
While the US company was assessing the offer, it said there was "no assurance" that any transaction would be "entered into or consummated."
Bayer released its own statement on Thursday, briefly confirming that its executives had met with counterparts in their acquisition target to "privately discuss" a merger.
Neither statement specified a price tag for the deal. But a bid to acquire Monsanto, which has a market capitalization of $42 billion (37.4 billion euros), is likely to be worth more than ChemChina's February deal to take over Swiss agrichemicals giant Syngenta for $43 billion. Monsanto itself tried to buy Syngenta last year.
A new seeds giant?
The scale of a Bayer-Monsanto merger could face resistance from antitrust regulatorsAgricultural suppliers like Monsanto have been hit by low commodity prices, causing farmers to cut down on supply orders. The strong US dollar has also made the company's products more expensive overseas.
The end of the first quarter saw Monsanto cut its earnings forecast for 2016.Leverkusen-based Bayer AG, which specializes in health care and agriculture, employs some 117,000 people worldwide and had sales last year of 46.3 billion euros ($52.22 billion).
The German company, whose farm business produces seeds as well as compounds to kill weeds, bugs and fungus, said the proposed acquisition would help it "create a leading integrated agriculture business."
Negative reaction
But the news sent Bayer shares tumbling over eight percent to a 2-1/2 year low of 88.39 euros in early Thursday trading, as some investors worried about the potential cost of a deal.
And according to analysts at Deutsche Bank, Monsanto's management is seeking a purchase price of around $150 per share, which would represent a huge mark-up on the current share price of around $97.
The analysts therefore felt a deal was unlikely because of the price, as well as possible reservations on the part of competition authorities toward a combination of Bayer and Monsanto.
Anlaysts at Credit Suisse also suggested that Bayer's financial firepower was "very limited" after it paid out 10 billion euros for the prescription-free drugs business of US firm Merck in 2014, a deal which has not really fulfilled Bayer's expectations so far.
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon